Oncology
 |
|
11 december 2019 07:02:49 |
| Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer (Future Oncology) |
|
Tweet Future Oncology, Volume 16, Issue 1, Page 4289-4301, January 2020. |
| 206 viewsCategory: Oncology |
 PABPC1 relevant bioinformatic profiling and prognostic value in gliomas (Future Oncology)Real-world incidence and cost of pneumonitis post-chemoradiotherapy for Stage III non-small-cell lung cancer (Future Oncology) 
|
| blog comments powered by Disqus |
MyJournals.org
The latest issues of all your favorite science journals on one page
The latest issues of all your favorite science journals on one page
